HER2-negative (1+) breast cancer with unfavorable prognostic features: To FISH or not to FISH?

Annals of Oncology

Volumn 23, Issue 5, 2012, Pages 1371-1372

  Iorfida, M ^a   Dellapasqua, S ^a   Bagnardi, V ^a   Cardillo, A ^a   Rotmensz, N ^a   Mastropasqua, M G ^b   Bottiglieri, L ^b   Goldhirsch, A ^a   Viale, G ^b   Colleoni, M ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC AGENT; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; TRASTUZUMAB;

BREAST CANCER; BREAST CARCINOGENESIS; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER PROGNOSIS; CHROMOSOME 17; CLINICAL EVALUATION; DRUG EFFICACY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC ASSOCIATION; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; LYMPH NODE METASTASIS; MOLECULARLY TARGETED THERAPY; ONCOGENE NEU; PREDICTIVE VALUE; PRIORITY JOURNAL;

EID: 84860459647     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds064     Document Type: Letter

References (4)

1. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
2. Akiyama T, Sudo C, Ogawara H et al. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986; 232: 1644-1646.
3. Jacobs TW, Gown AM, Yaziji H et al. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 1999; 17: 1983-1987.
4. Dybdal N, Leiberman G, Anderson S et al. Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab. Breast Cancer Res Treat 2005; 93: 3-11.